Circulating tumor DNA in head and neck squamous cell carcinoma—current status and future prospects DOI
Samuel Auger, Vasudha Mishra, Alka Singh

и другие.

Academia oncology., Год журнала: 2024, Номер 1(2)

Опубликована: Дек. 19, 2024

Squamous cell carcinoma (SCC) is the most common malignancy of head and neck. Stagnating survival rates in recent decades, despite advances treatment paradigms, surveillance technologies, multidisciplinary care, leave clinicians with a need for better options screening, risk-stratifying, monitoring patients. A growing proportion patients HPV-associated SCC have improved outcomes but continue to heterogenous response treatment. Advances platforms assays measuring circulating tumor DNA offer an opportunity monitor disease status at molecular level both virally mediated traditional risk-factor-driven This overview will discuss experimental, clinically used, commercially available liquid biopsy their applications neck malignancies.

Язык: Английский

Circulating HPVDNA in patients undergoing transoral robotic surgery for oropharyngeal cancer: liquid biopsy could identify molecular residual disease DOI
Flaminia Campo, Francesca Paolini, Irene Terrenato

и другие.

European Archives of Oto-Rhino-Laryngology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 25, 2025

Язык: Английский

Процитировано

1
From infection to immortality: The role of HPV and telomerase in head and neck cancer DOI Creative Commons
Silvia Giunco, Annarosa Del Mistro, Marzia Morello

и другие.

Oral Oncology, Год журнала: 2025, Номер 161, С. 107169 - 107169

Опубликована: Янв. 5, 2025

Язык: Английский

Процитировано

0
Therapeutic options for human papillomavirus‐positive tonsil and base of tongue cancer DOI Creative Commons
Mark Zupancic,

Ourania N. Kostopoulou,

Linda Marklund

и другие.

Journal of Internal Medicine, Год журнала: 2025, Номер unknown

Опубликована: Апрель 17, 2025

Abstract The incidences of human papillomavirus‐positive (HPV + ) tonsillar and base tongue squamous cell carcinomas (TSCC BOTSCC) have increased in recent decades. Notably, HPV TSCC BOTSCC a significantly better prognosis than their HPV‐negative counterparts when treated with current surgical options, radiotherapy, or intensified chemoradiotherapy. However, cure is not achieved 20% patients TSCC/BOTSCC. Meanwhile, cured often present severe chronic side effects. This necessitates novel tailored alternatives, such as targeted therapy, immune checkpoint inhibitors (ICIs), treatment de‐escalation, together follow‐up. Current precision medicine therefore focuses on detecting predictive driver cancer genes to stratify patient treatment, provide those poor prognostic markers select favorable for de‐escalated therapy. Moreover, cell‐free DNA (cfHPV DNA) plasma before after has been attempted improve In this context, perspective discusses the significance optimally defining status, which requires p16 INKa overexpression, using markers, high CD8 T‐cell counts E2 mRNA expression, tumor size, following cfHPV selection specific therapies. Clinical trials ICI with/without chemotherapy, therapy inhibitors—such phosphoinositide 3‐kinase fibroblast growth factor receptor inhibitors—or various HPV‐based vaccines treating recurrences yielded promising results.

Язык: Английский

Процитировано

0
Update zu HPV-assoziierten Kopf-Hals-Karzinomen – Highlights der ASCO-Jahrestagung 2024 DOI
Shachi Jenny Sharma, Jens Peter Klußmann,

Johannes Döscher

и другие.

HNO, Год журнала: 2024, Номер 72(12), С. 843 - 849

Опубликована: Окт. 25, 2024

Процитировано

1
Multidisciplinary approach in head and neck cancer DOI Creative Commons
Cláudio Roberto Cernea, Ana Kober Nogueira Leite,

Bruno Figueiredo Muller

и другие.

Einstein (São Paulo), Год журнала: 2024, Номер 22(Suppl 3)

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

0
Circulating HPV Tumor DNA and Molecular Residual Disease in HPV-Positive Oropharyngeal Cancers: A Scoping Review DOI Creative Commons
Andrea Migliorelli, Andrea Ciorba, M Manuelli

и другие.

Diagnostics, Год журнала: 2024, Номер 14(23), С. 2662 - 2662

Опубликована: Ноя. 26, 2024

The aim of this review is to assess the utility circulating HPV tumor DNA (ctHPVDNA) clearance in monitoring molecular residual disease HPV-related oropharyngeal squamous cell carcinoma (OPSCC) patients. Recently, ctHPVDNA patient plasma was found be a promising biomarker for OPSCC. Changes appear associated with treatment response and may useful identifying disease. A literature performed using PubMed/MEDLINE, EMBASE, Cochrane Library databases according PRISMA criteria scoping reviews (from 2017 July 2024). total 5 articles 562 patients have been included. Three studies examine role CRT, while remaining two consider surgery as option. results indicate that has potential serve valuable assessment Further are required confirm efficacy marker stratifying group

Язык: Английский

Процитировано

0
Circulating tumor DNA in head and neck squamous cell carcinoma—current status and future prospects DOI
Samuel Auger, Vasudha Mishra, Alka Singh

и другие.

Academia oncology., Год журнала: 2024, Номер 1(2)

Опубликована: Дек. 19, 2024

Squamous cell carcinoma (SCC) is the most common malignancy of head and neck. Stagnating survival rates in recent decades, despite advances treatment paradigms, surveillance technologies, multidisciplinary care, leave clinicians with a need for better options screening, risk-stratifying, monitoring patients. A growing proportion patients HPV-associated SCC have improved outcomes but continue to heterogenous response treatment. Advances platforms assays measuring circulating tumor DNA offer an opportunity monitor disease status at molecular level both virally mediated traditional risk-factor-driven This overview will discuss experimental, clinically used, commercially available liquid biopsy their applications neck malignancies.

Язык: Английский

Процитировано

0